Abstract 1553P
Background
Production of IL6 by the tumor stroma of esophageal adenocarcinoma (EAC) causes epithelial-to-mesenchymal transition of tumor cells and resistance to chemoradiation (Ebbing et al. 2019). Serum ADAM12 protein levels measure stroma activity (Veenstra et al. 2018) whilst IL6 and IL6R monitor IL6 inhibition (Nishimoto et al. 2008). Here, we aim to demonstrate that targeting stroma with tocilizumab in EAC patients increases efficacy of chemoradiation.
Methods
This was a multicenter, randomized, open label, phase II proof-of-concept trial in 48 patients with resectable EAC. Patients were stratified for serum ADAM12 (cutoff of 203 pg/mL) and randomized for standard of care chemoradiation according to the CROSS regimen or addition of tocilizumab to standard of care, followed by surgery. Tocilizumab 8 mg/kg with a maximum of 800 mg was given intravenously for three cycles. Serum ADAM12, IL6 and IL6R was measured at baseline, during treatment, at resection and three months thereafter. Primary endpoint was histopathological response to chemoradiation according to the Mandard score.
Results
After inclusion of 36 patients, the trial was discontinued due to safety concerns. Perforation of the esophageal wall was observed in 3/20 (15%) of patients in the intervention arm compared to 0/16 (0%) in the control arm. There was no significant difference in Mandard score between treatment arms (p = 1.000). Patients treated with tocilizumab had significantly higher serum levels of IL6 and IL6R during treatment (p < 0.0001). Baseline ADAM12 was not associated with histopathological response to tocilizumab (p = 0.672). There was no difference in serum ADAM12 levels over time between treatment arms.
Conclusions
Addition of tocilizumab to neoadjuvant chemoradiation in patients with EAC is unsafe and should not be considered for clinical practice. Potentially, concurrent inhibition of IL6 impairs wound healing whilst chemoradiation obliviates the tumor in the esophageal wall, increasing the risk for perforation. We plan to investigate this hypothesis with RNA sequencing, immunohistochemistry, cytokine profiling, and flow cytometry of peripheral blood mononuclear cells and tumor biopsies.
Clinical trial identification
NCT04554771.
Editorial acknowledgement
Legal entity responsible for the study
Amsterdam UMC, location AMC.
Funding
Oncode Institute.
Disclosure
M. van Berge Henegouwen: Financial Interests, Institutional, Advisory Role, Consultant, unrelated to present study: Mylan, Johnson & Johnson, Alesi Surgical, B. Braun, Medtronic; Financial Interests, Institutional, Funding, Unrestricted, unrelated to present study: Stryker. R.E. Pouw: Financial Interests, Institutional, Advisory Role, Consultant: MicroTech Europe, Medtronic BV.; Financial Interests, Institutional, Invited Speaker: Pentax; Financial Interests, Institutional, Advisory Board: EsoCap AG. N.C. van Grieken: Financial Interests, Institutional, Advisory Board, Unrelated to present study: Bristol Myers Squibb, Merck Sharp & Dohme. J. Medema: Financial Interests, Institutional, Advisory Role, Unrelated to present study: AbbVie. S. Derks: Financial Interests, Institutional, Advisory Role, Unrelated to the present study: Bristol Meyers Squibb; Financial Interests, Institutional, Funding, Unrelated to the present study: Incyte; Financial Interests, Institutional, Invited Speaker, Unrelated to the present study: Benecke, Medtalks, Novartis, Servier. M.F. Bijlsma: Financial Interests, Institutional, Funding, Unrelated to present study: Celgene, Lead Pharma; Financial Interests, Institutional, Advisory Role, Consultant: Servier. H.W.M. Van Laarhoven: Financial Interests, Institutional, Advisory Board: BMS, MSD; Financial Interests, Personal, Invited Speaker: Lilly; Financial Interests, Institutional, Writing Engagement: Nordic Pharma; Financial Interests, Institutional, Invited Speaker: Servier; Financial Interests, Institutional, Research Grant, REPEAT study: Bayer; Financial Interests, Institutional, Research Grant: BMS, Philips; Financial Interests, Institutional, Local PI, FRACTION study: BMS; Financial Interests, Institutional, Research Grant, ACTION study: Celgene; Financial Interests, Institutional, Research Grant, DECO study: Janssen; Financial Interests, Institutional, Local PI, RAINFALL study: Lilly; Financial Interests, Institutional, Local PI, KEYNOTE 062 and KEYNOTE 181 study: Merck/MSD; Financial Interests, Institutional, Research Grant, SOX study: Nordic Pharma; Financial Interests, Institutional, Research Grant, TRAP study, PERFECT study; local PI of JACOB study: Roche; Financial Interests, Institutional, Research Grant, LyRICX study: Servier; Financial Interests, Institutional, Research Grant, TAPESTRY study: Merck; Financial Interests, Institutional, Research Grant, Research money and investigational product: Incyte; Non-Financial Interests, Institutional, Product Samples, For all clinical study mentioned, study medication is provided: See 'research funding'. All other authors have declared no conflicts of interest.
Resources from the same session
1468P - Patients’ perspective on tolerability of dostarlimab in NSCLC: Patient-reported outcomes from the phase II PERLA trial
Presenter: Martin Reck
Session: Poster session 21
1469P - The role of the CXCL12/CXCR4 pathway in the immunotherapy of non-small cell lung cancer
Presenter: Jacobo Rogado
Session: Poster session 21
1470P - Statin use and overall mortality in patients with advanced non-small cell lung cancer receiving anti-PD(L)1 immunotherapy: A SEER Medicare database analysis
Presenter: Joshua Reuss
Session: Poster session 21
1471P - Immunotherapy prolongs long-term real-world survival compared to chemotherapy for metastatic non-small cell lung cancer: A propensity score-matched analysis
Presenter: Kun Kim
Session: Poster session 21
1472P - Radiotherapy affects immunotherapy efficacy based on tumor mutation status in patients with metastatic NSCLC
Presenter: Shenduo Li
Session: Poster session 21
1473P - Efficacy of anti-PD1/PDL1 antibody monotherapy in patients with advanced non-small cell lung cancer with increased hepcidin expression
Presenter: Masaki Yamamoto
Session: Poster session 21
1474P - Outcome of nivolumab and ipilimumab-based therapy for advanced non-small cell lung cancer with low or negative PD-L1 expression
Presenter: Takafumi Fukui
Session: Poster session 21
1475P - Torque teno virus DNA load as biomarker for tumor response to mono immune checkpoint inhibition in non-small cell lung cancer
Presenter: Benthe Muntinghe
Session: Poster session 21
1476P - Outcomes to first-line pembrolizumab in patients with advanced NSCLC and high PD-L1 expression: A Spanish multicentric study
Presenter: Aida Piedra
Session: Poster session 21
1477P - STK11 mutations predict poor prognosis for advanced NSCLC treated with first-line immunotherapy or chemo-immunotherapy according to KRAS, TP53, KEAP1, and SMARCA4 status
Presenter: Andrea De Giglio
Session: Poster session 21